A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)

BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Genitourin Cancer
Main Authors: Kanesvaran, R., Watt, K., Turnbull, J. D., Armstrong, A. J., Cohen-Wolkowiez, M., George, D. J.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/
https://ncbi.nlm.nih.gov/pubmed/26174223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker